osimertinib
Selected indexed studies
- Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. (J Hematol Oncol, 2022) [PMID:36482474]
- A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib. (Sci Rep, 2022) [PMID:36380085]
- Acquired resistance mechanisms to osimertinib: The constant battle. (Cancer Treat Rev, 2023) [PMID:37060646]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. (2022) pubmed
- A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib. (2022) pubmed
- Acquired resistance mechanisms to osimertinib: The constant battle. (2023) pubmed
- MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC. (2024) pubmed
- Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance. (2023) pubmed
- Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis. (2023) pubmed
- Neoadjuvant and Adjuvant Osimertinib in Stage IA to IIIA, EGFR-Mutant NSCLC (NORA). (2025) pubmed
- Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC. (2022) pubmed
- Osimertinib plus platinum-pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study. (2021) pubmed
- The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies. (2024) pubmed